Furthermore, the distinct mechanisms of action of PD-1 and CTLA-4 pathway blockade, along with the observed synergistic anti-tumor effects of combined treatment in preclinical models (37–39), led to the clinical evaluation of these two ICIs for cancer patients, demonstrating an enhanced clinical response (40). Here, CTLA4 is linked to cancer.